|
|
|
"Meningococcal disease is a devastating illness that can result in rapid death or have long-lasting repercussions for survivors and their families," said Andrin Oswald, CEO of Novartis Vaccines and Diagnostics. There is no vaccine currently licensed in the US for use in infants.
Novartis Vaccines is a global leader in providing vaccines to protect against deadly meningococcal disease. Even with early and appropriate treatment, between 10% and 14% of meningitis cases are fatal, typically within 24 to 48 hours[4],[5]. In 2008, the Group's continuing operations achieved net sales of USD 41.com. February 2008 update. Meningococcal meningitis Fact sheet. Studies will shortly be initiated to further explore AEOL 10150's ability to protect the skin and lungs from damage due to exposure to mustard gas, and to protect the lungs from exposure to chlorine gas.
get xanax no rx needed high on xanax tylenol and xanax xanax before pregnant xanax generic xanax withdrawal side effects xanax withdrawl side effects xanax xr 2 mg
Novartis Vaccines is the world's fifth-largest vaccines manufacturer and second-largest supplier of flu vaccines in the US.
Five serogroups cause the majority of meningococcal disease worldwide: A, B, C, W-135 and Y[1]. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. 2008;299(2): 173-184 [2. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.2 billion was invested in R&D activities throughout the Group. The product also has an established stability profile that permits long-term storage. The BLA was submitted on August 28, 2008 for use of Menveo in subjects age 11 - 55.
About Novartis
Novartis Vaccines and Diagnostics is a division of Novartis focused on the development of preventive treatments. Research has shown that ROS and RNS have important cell signaling roles, and through its interaction with RNS and ROS, AEOL 10150 appears to have multiple mechanisms of action including anti-oxidant, anti-inflammatory and anti-angiogenic activities.
|
|
No News has been posted yet
|
|
|
Forgotten your password? Request a new one here.
|
 Guests Online: 1
No Members Online
Registered Members: 1
Unactivated Members: 0
Newest Member: Owen Electrical
|
|
v6.01.1 © 2003-2005